ArticleNPJ digital medicine2026
AI-guided personalized predictions on myopia progression and interventions.
Article in NPJ digital medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- EGS-Net: a knowledge-augmented machine learning framework for predicting future high-myopia risk from longitudinal school-screening trajectories.Frontiers in medicine · 2026Article
- Cellular Biological Basis and Novel Breakthroughs in the Pathogenesis of Myopia - A Narrative Review.International journal of general medicine · 2026Review
- From static guidelines to dynamic personalization: a novel AI-driven evidence-based paradigm for low-concentration atropine prescribing in myopia control.Frontiers in medicine · 2026Article
- SSR-stacking: a hybrid GNN-ensemble framework for high-myopia classification under simulated baseline-SE missingness.Frontiers in public health · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors.
Funding
Abstract
Myopia is a major global health concern. To enable precision myopia management, we developed a Transformer-based artificial intelligence (AI) model, the Myopia Progression Predictive Model (MPPM), comprising two modules: the Natural Progression Module (NPM) for predicting untreated myopia progression and the Intervention Progression Module (IPM) for forecasting progression under specific interventions. NPM was trained on 1,109,827 refractive records from 304,353 children and adolescents, achieving high predictive accuracy for future spherical equivalent (SE) and axial length (AL) over a 10-year period. In the internal test set, SE prediction reached R² = 0.94, MAE = 0.35D; for AL, R² = 0.91, MAE = 0.16 mm. Comparable performance was observed in external validation. IPM was trained on four intervention cohorts (0.01% atropine, orthokeratology, peripheral defocus spectacles, and repeated low-level red light [RLRL] therapy) using a Transformer-based causal machine learning framework, enabling individualized estimation of treatment effects. It accurately predicted myopia changes under each intervention (SE: R² > 0.88, MAE < 0.45D; AL: R² > 0.80, MAE < 0.31 mm). Among the interventions, RLRL slightly reversed myopia progression, whereas the others slowed myopia progression. MPPM demonstrates strong promise as an AI-driven platform for personalized prediction and optimization of pediatric myopia management.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.